{"url_path":"/sec/prok/10-q/2026/item-6","section_key":"item-6","section_title":"Item 6 Exhibits.","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-15","source_url":"https://www.sec.gov/Archives/edgar/data/1850270/0001193125-26-225841-index.html","accession_number":"0001193125-26-225841","cik":"0001850270","ticker":"PROK","issuer_name":"PROKIDNEY CORP.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1850270/0001193125-26-225841-index.html","primary_entity_key":"0001850270","primary_entity_name":"PROKIDNEY CORP."},"word_count":309,"has_tables":true,"body_markdown":"Item 6. Exhibits.\n\n \n\nExhibit\n\nNumber\n\nDescription\n\n \n\n \n\n \n\n31.1*\n\n[Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.](prok-ex31_1.htm)\n\n \n\n \n\n \n\n31.2*\n\n[Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.](prok-ex31_2.htm)\n\n \n\n \n\n \n\n32.1*\n\n[Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.](prok-ex32_1.htm)\n\n \n\n \n\n \n\n32.2*\n\n[Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.](prok-ex32_2.htm)\n\n30\n\n \n\n \n\n \n\n \n\n101*\n\nThe following materials from the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2026, formatted in iXBRL (Inline Extensible Business Reporting Language): (i) Condensed Consolidated Balance Sheets (unaudited), (ii) Condensed Consolidated Statements of Operations (unaudited), (iii) Condensed Consolidated Statements of Comprehensive Loss (unaudited), (iv) Condensed Consolidated Statements of Changes in Redeemable Noncontrolling Interest and Stockholders’ Deficit (unaudited), (v) Consolidated Statements of Cash Flows (unaudited) and (vi) Notes to Condensed Consolidated Financial Statements (unaudited), tagged as blocks of text and including detailed tags.\n\n \n\n \n\n \n\n104*\n\n \n\nThe cover page from this Quarterly Report on Form 10-Q for the quarter ended March 31, 2026, formatted in Inline XBRL.\n\n \n\n \n\n \n\n \n\n† Management contract or compensatory plan or arrangement\n\n* Filed herewith.\n\n \n\n31\n\n \n\nSIGNATURES\n\nPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on\n\nits behalf by the undersigned thereunto duly authorized.\n\n \n\nPROKIDNEY CORP.\n\nDate: May 15, 2026\n\nBy:\n\n/s/ Bruce Culleton\n\nName: Bruce Culleton\n\nTitle: Chief Executive Officer\n\n \n\n \n\n \n\n(Principal Executive Officer)\n\n \n\nDate: May 15, 2026\n\nBy:\n\n/s/ James Coulston\n\nName: James Coulston\n\nTitle: Chief Financial Officer\n\n \n\n \n\n \n\n(Principal Financial and Accounting Officer)\n\n \n\n \n\n \n\n32"}